Maxim Group analyst Jason McCarthy maintained a Buy rating on Gain Therapeutics (GANX – Research Report) yesterday and set a price target of $5.00.
Jason McCarthy’s rating is based on Gain Therapeutics’ promising developments in their clinical-stage biotechnology efforts, particularly with their lead drug candidate, GT-02287. This drug is in clinical trials for Parkinson’s disease and has shown encouraging results in early studies, such as a significant increase in GCase activity in healthy subjects, which suggests potential efficacy in Parkinson’s patients.
The company’s financial position appears stable, with sufficient funding projected through the second half of 2025, allowing them to continue their Phase 1b trial without immediate financial concerns. Additionally, the upcoming interim data from this trial, expected by the end of the second quarter of 2025, could serve as a significant catalyst for the stock. These factors, combined with a strategic focus on allosteric therapies and a robust preclinical data package, underpin McCarthy’s optimistic outlook and Buy rating for Gain Therapeutics.
McCarthy covers the Healthcare sector, focusing on stocks such as Medicus Pharma Ltd, SELLAS Life Sciences Group, and Lipella Pharmaceuticals, Inc.. According to TipRanks, McCarthy has an average return of -18.6% and a 26.41% success rate on recommended stocks.
In another report released today, Scotiabank also maintained a Buy rating on the stock with a $12.00 price target.